This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Myriad Genetics - Upgrades & Downgrades

NEW YORK ( TheStreet) -TheStreet Ratings' stock model downgraded Myriad Genetics Inc (MYGN - Get Report) to 'Hold' from 'Buy'. Net income at this $1.8 billion market cap, health diagnostics company shrank by 31.6% to $24.2 million in the fiscal second quarter compared to the year earlier quarter.

TheStreet Ratings released rating changes on seven U.S. common stocks for January 28, 2011. In total, three stocks were upgraded and four stocks were downgraded by our stock model.

In the fiscal second quarter, Myriad Genetics reported $100.4 million in revenue, an increase of 8.3% compared to the year earlier quarter. Learn more about Myriad Genetics: Company Profile, Income Statement, Balance Sheet, Stock Ratios, Analyst Ratings.

$658 million market cap, pharmaceutical company, Simcere Pharmaceutical Group ADR (SCR) was upgraded to 'Buy' from 'Hold'. In third quarter results, Simcere Pharmaceutical Group turned in a profit of $8.3 million, an increase of 243.6% when compared to the year earlier quarter. Over the same time period, revenue grew by 29.4% to $80.2 million. Learn more about Simcere Pharmaceutical Group: Company Profile, Income Statement, Balance Sheet, Stock Ratios, Analyst Ratings.

-- Reported by Kevin Baker in Jupiter, FL.



For additional Investment Research check out our Ratings Research Center.

Kevin Baker became the senior financial analyst for TheStreet Ratings upon the August 2006 acquisition of Weiss Ratings by TheStreet.com, covering mutual funds. He joined the Weiss Group in 1997 as a banking and brokerage analyst. In 1999, he created the Weiss Group's first ratings to gauge the level of risk in U.S. equities. Baker received a B.S. degree in management from Rensselaer Polytechnic Institute and an M.B.A. with a finance specialization from Nova Southeastern University.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
MYGN $35.34 -0.44%
AAPL $124.75 -1.13%
FB $80.78 -1.86%
GOOG $524.05 -1.83%
TSLA $206.79 0.04%

Markets

DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs